Objectives: A current trend in total hip replacement (THR) is the use of minimally invasive surgery. Little is known, however, about the impact of minimally invasive THR on resource use and length of stay. This study analyzed the effect of minimally invasive surgery on hospital costs and length of stay in German hospitals compared with conventional treatment in THR. Methods: We used patient-level administrative hospital data from three German hospitals participating in the national cost data study. We conducted a propensity score matching to account for baseline differences between minimally invasively and conventionally treated patients. Subsequently, we estimated the treatment effect on costs and length of stay by conducting group comparisons, via paired t tests and Wilcoxon signed-rank tests, and regression analyses. Results: The three hospitals provided data from 2886 THR patients. The propensity score matching led to 812 matched pairs.
Introduction
Total hip replacement (THR) has been described as "the operation of the century" [1] . It is a high-volume surgical procedure [2] that is considered to be successful for the treatment of diseases such as coxarthrosis [3] . With approximately 200,000 procedures each year, hip replacement is one of the most frequent kinds of surgery in German hospitals [4] . Because of demographic change and the increasing use of this procedure in older age groups, the demand for hip replacement is expected to increase further [5] [6] [7] [8] . In recent years, there is a trend of using minimally invasive (MI) surgery approaches in THR [1] . MI surgery approaches were developed on the basis of conventional approaches and are supposed to reduce pain, postoperative blood loss, rehabilitation time, and length of hospital stay [9] . Similar to conventional procedures in THR, a variety of different MI approaches exist [10] but a coherent definition of MI THR is lacking [11] . In some articles, an MI THR is defined by the length of incision (Ͻ10 cm) [12] [13] [14] [15] , whereas in other articles, it is defined by the minimization of tissue and muscle dissection [16] . Although a number of studies have been published that compare MI THR with conventional THR, evidence about its relative merits is still limited [10, [17] [18] [19] . In particular, the direct costs of an MI procedure in THR for hospitals have hardly been studied [20] despite the fact that, given the high number of THR procedures, even slight changes in direct costs can be expected to be important for the respective hospitals.
In this study, we assessed the effect of MI THR surgery on direct hospital costs and length of stay (LOS) in German hospitals compared with the effect of convention surgery for THR.
Material and Methods
We used patient-level administrative hospital data from German hospitals participating in the national cost data study conducted by the Institute for the Hospital Remuneration System. The data include sociodemographic, medical, and treatment information, as well as cost data. Hospitals participating in the national cost data study use a standardized cost accounting approach, reporting direct hospital costs in 99 cost categories. Treatment information includes type of treatment, provided by the German procedure codes (Operationen-und Prozedurenschlüssel [OPS]), and date of treatment. Medical information is given by International Statistical Classification of Diseases, 10th Revision, German Modification (ICD-10-GM) (Version 2008), including principal and secondary diagnoses recorded during hospital admission, along with conditions acquired or developed during the hospital stay. A distinction be-tween diagnosis at admission and conditions acquired at the hospital is only partially possible as the administrative data in Germany do not formally make this differentiation.
From approximately 250 hospitals, 31 that participated in the national cost data study provided patient-level data from the year 2008. We identified patients with a recorded primary THR by using the first five digits of the OPS codes 5-820.0x and 5-820.2x. As no specific OPS code exists for MI THR, we classified patients as MI treated if the OPS code 5-986 "minimally invasive technique" was recorded. Patients who had also undergone a revision hip arthroplasty, identified by OPS code 5-821.xx, were excluded from the analysis. Hospitals with either no conventional THR or no MI THR were excluded, as we aimed to compare MI and conventional cases from the same hospitals.
We contacted the remaining hospitals and asked 1) whether they coded MI THR consistently via the OPS code 5-986 and 2) which treatment patterns were a prerequisite for coding a patient as MI THR. After consultation with the relevant professional medical association, we included only those hospitals in the sample that consistently coded MI THR via the OPS code 5-986 given a surgical approach that minimizes tissue and muscle dissection. The hospitals kept in the sample were recontacted and were asked to provide data from 2009.
For our outcome variable "total cost", we summed up all reported costs. To allow further analysis, we grouped the 99 cost categories into the following 7 categories: staff costs-medical service; staff costs-nursing service; staff costs-medical-technical service; pharmaceutical costs; implant costs; costs for further medical devices; and overhead costs.
We calculated the LOS as the difference between the date of admission and the date of discharge. We also divided the LOS into further categories: preoperative LOS (pre-LOS), the difference between the date of admission and the date of surgery, and postoperative LOS (post-LOS), the difference between the date of surgery and the date of discharge.
Using observational studies for the analysis of treatment effect suffers from one drawback in comparison with randomized controlled trials: Individuals who receive treatment (MI surgery) are likely to differ in various baseline characteristics from those who do not (conventional surgery). These differences may affect the outcome, leading to biased estimates of the treatment effect [21] . Nevertheless, using administrative data has some advantages: it allows for treatment to be examined as it occurs in routine clinical care [22] and includes relatively large sample sizes [23] . Since individuals in routine clinical care are not randomly assigned for treatment, methods adjusting for the missing randomization have to be applied [24] . To address the treatment-selection bias, we applied propensity score matching [25] . In the propensity score method, all covariates that might predict treatment and influence the outcome are reduced into a single score, which represents the probability of treatment assignment conditional on observed background covariates [26] . Assuming that no other confounders exist, matching on propensity scores mimics a randomized treatment assignment, with matched treated and untreated individuals having the same probability of being treated.
We estimated the probability of selection for MI surgery (the propensity scores) by using multivariate logistic regression analysis. In the model we included all potential confounders, that is, factors that had been reported to be associated with both treatment selection and outcome (costs and LOS). We identified confounders on the basis of a literature search, leading to a total of four confounding factors for our propensity score model: age [27] [28] [29] [30] [31] , sex [27, 28, 30, 31] , obesity [32] [33] [34] [35] , and the diagnosis indicating the THR (e.g., coxarthrosis or osteonecrosis) [27] . Since according to previous studies various factors are associated with LOS and hospital costs and an extended LOS has been associated with an increase in resource use [29, 30, 36, 37] , we used the same propensity scores and consequently the same matched sample for both variables of interest (total costs and LOS).
In addition, we included dummy variables indicating the hospital of treatment, because this approach has been reported suitable to account for a hierarchical data structure (in our study, patients treated in hospitals) [38] . To avoid confounding by different years of the data, we conducted a subgroup matching. We first calculated the propensity scores and conducted the matching for each year separately. Subsequently, we merged the 2008 and 2009 data.
The matching was conducted by using a one-to-one caliper matching with replacement. On the basis of previously published studies, we chose a caliper width of 0.2 of the SD of the logit of the propensity score [39] and assessed the matching quality by using standardized differences [40] . We rated standardized differences of up to 10% between the covariates as adequately balanced [41] . After the matching, we excluded all nonmatched cases from the sample and conducted all further statistical analysis by using the matched sample.
The effect of the treatment strategy was analyzed in two steps. In a first step, differences between the two treatment groups in our outcome variables (costs and LOS), as well as in the respective subgroups, were assessed by using paired t test and, as a nonparametric alternative, Wilcoxon signed-rank test.
In a second step, we applied generalized linear models (GLMs) to estimate the effect of an MI treatment on total costs and LOS. We used generalized estimating equations to account for the matched data structure. In the GLMs, we controlled for additional factors that had been associated with hospital costs and LOS: further treatment strategies, such as acetabular roof construction; type of implant (cementless, cemented, or hybrid) [29, 42, 43] ; type of admission (emergency or elective) [44] ; and comorbidities assessed through the Charlson index [37] . We included these factors only in the GLMs but not in the propensity score matching either because they were not related to treatment selection or because they could not be determined before treatment. In the GLMs with LOS as the dependent variable, we specified a model with a Poisson distribution and a log-link. For the dependent variable total cost, we specified a model with a normal distribution and the natural log of the costs as the dependent variable.
In the propensity score model and the GLMs, we included all factors using dummy variables, except for the continuous variable age. The value of the dummies was set as 1 if the treatment or the diagnosis had been reported and as 0 if it had not been reported. We retrieved all necessary information from the sociodemographic and medical information included in the administrative electronic patient files. Obese patients (body mass index Ͼ 30 kg/m 2 ) were identified by using the ICD-10 code E66. To include the diagnosis leading to the THR, we grouped the cases according to their main diagnosis. If a case had a primary diagnosis not related to THR, we screened all secondary diagnoses and grouped according to those. Finally, we grouped the diagnosis into the five dummy variables: coxarthrosis, fracture, arthritis, osteonecrosis, and others.
In addition, we applied the enhanced ICD-10 -based version of the Charlson index [45, 46] to account for comorbidities. Following this approach, we first calculated a weighted global Charlson index score by identifying the relevant ICD-10 codes recorded as secondary diagnoses and by overweighting the 6 most severe among the 17 dimensions of comorbidity proposed by Charlson: the "Hemiplegia/Paraplegia," "Renal disease," and "Cancer (any malignancy)" comorbidities are weighted by a coefficient 2, cases of "Moderate or severe liver diseases" by a coefficient 3, and "Metastatic solid tumor" and the "AIDS/HIV" cases by a coefficient 6 (see Charlson et al. [45] for details). We then used the Charlson index score to group patients into two dummy variables: Charlson1 (patients suffering from one single nonsevere comorbidity; Charlson score ϭ 1) and Charlson2 (patients suffering from at least one severe or two nonsevere comorbidities; Charlson score Ͼ 1).
In all statistical analysis, a P value of Յ0.05 was considered statistically significant. All statistical analyses were performed with SAS 9.2.
Results
The 31 hospitals providing data for our study had an average of 448 beds. Most hospitals were private not-for-profit hospitals (n ϭ 19), followed by public hospitals (n ϭ 10) and private for-profit hospitals (n ϭ 2). From the 31 hospitals in our data, we had to exclude 28 hospitals because of no THR cases, no MI cases, or inconsistent coding of MI cases.
The remaining three hospitals provided the additional data from 2009, leading to a final sample of three hospitals and 2886 cases. Compared with the total sample, the remaining hospitals had fewer beds on average (mean ϭ 300) and they were all private not-for-profit hospitals.
In the three hospitals, MI THR was defined by reduced tissue and muscle dissection. The sample characteristics are displayed in Table 1 . A total of 812 (28.14%) patients were treated with MI surgery. The average age of the patients was 67 years, and 60.33% were women. Coxarthrosis was the most frequent diagnosis (90.61%), followed by arthritis (4.23%), osteonecrosis (2.22%), and fractures (1.56%). It was found that 1.39% of the patients had none of these diagnoses and was summed up in the group "other diagnosis." In the sample, 18.71% of the patients were coded as obese, 18.02% had a Charlson score of 1, and 4.44% had a Charlson score above 1. In more than 80% of the cases, cementless prostheses were used, followed by hybrid prostheses (15.59%) and cemented prostheses (2.08%). Acetabular roof reconstruction was found in 1.14% of the patients, and osteosynthesis equipment was used in 0.62% of the cases.
The average LOS was 11.85 Ϯ 3.86 days with a minimum LOS of 2 days and a maximum LOS of 75 days. The average pre-LOS was 1.27 Ϯ 2.13 days, and the average post-LOS was 10.66 Ϯ 3.35 days.
The total direct hospital costs ranged from €3,364 to €27,960 with a mean of €6,146 Ϯ €1,340. The overhead costs were responsible for the largest share of total costs, followed by implant costs, staff costs (nursing service, medical service, and medical-technical service), costs for medical devices, and pharmaceutical costs. Matching on the propensity scores resulted in a total of 812 matches; thus, every MI case could be matched to a conventional case. Differences in the unmatched sample indicate that conventionally treated patients were older, were more likely women, and were more likely obese. MI treated patients were more likely to have coxarthrosis as the main diagnosis. After matching the patients along covariates and cluster variables, the standardized differences reduced substantially, from between 0.47% and 137.39% in the unmatched sample to between 0.25% and 6.65% in the matched sample (see Appendix Table 1 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2012.06.008). According to the predefined threshold of 10%, we rated the matched sample as adequately balanced.
After the matching, the differences between the conventionally and the MI treated cases consisted in further treatment strategies and comorbidities. The biggest difference was regarding the kind of prosthesis, as MI patients were more likely to have a cementless prosthesis (82.39% vs. 90.39%) while conventional patients were more likely to receive a hybrid prosthesis (12.07% vs. 7.76%). Conventionally treated patients also experienced more severe comorbidities; 11.08% of the patients had a Charlson score of 1 and 7.27% had a Charlson score above 1, compared with 13.18% and 4.10% of the MI treated patients, respectively.
The results of the group comparisons are shown in Tables  2 and 3 . In the matched sample, conventionally treated patients who were compared with MI treated patients had a significantly longer LOS (11.49 days vs. 10.90 days) and post-LOS (10.29 days vs. 9.71 days). In the unmatched sample, the difference in LOS between conventionally and MI treated patients was higher than in the matched sample (12.22 days vs. 10.90 days).
While we found a slight but nonsignificant difference in the total cost between MI (€5986) and conventional (€6018) cases in the matched sample, we found significant differences in the other cost categories. For conventionally treated patients, significantly higher costs were reported for overhead costs and all staff cost categories, that is, medical service, nursing service, and medical-technical service. Only the reported implant costs were significantly higher for the MI cases. In the unmatched sample, however, we found a bigger difference in the total cost between MI and conventional cases (€6208 vs. €5986). It has to be considered though that differences in the P value between the matched and unmatched group comparisons are also determined by the different sample sizes. Table 4 displays the allocation of costs for conventional and MI cases. In both groups, overhead costs account for the highest share of total costs, with 27% in the conventional surgery group and 26% in the MI surgery group, followed by implant costs, which account for 23% and 25%, respectively.
The results from the GLMs (Tables 5 and 6 ) are consistent with the prior results from the group comparisons: an MI treatment significantly reduced LOS, but there was no significant effect on total costs.
Discussion
A total of 812 matched pairs resulted from the propensity score matching. Thus, every MI THR case was matched with a conventional THR control and no MI THR cases had to be excluded.
The results of the group comparisons show that MI treated THR patients have a significantly shorter LOS and post-LOS, controlling for diagnosis, age, sex, obesity, hospital, and year of treatment. We found no significant difference in the total cost between MI and conventional cases, but we found differences in the cost categories, with implant costs as the only cost category significantly higher for MI treated patients. Differences in implant cost are partly explained by different implants for conventional and MI THR but are also because MI patients more frequently were given the more expensive cementless prostheses [42, 43] . Staff costs and overhead costs were significantly higher in conventionally treated patients. The allocation of costs shows that overhead as well as implant costs account for the majority of the total costs. Thus, our results suggest that despite differences in terms of LOS, the lack of significant total cost difference between the two treatment groups is due to the higher implant costs for MI patients. This finding is consistent with a previous study showing that implant costs are a major cost driver in THR [36] .
The results of the GLMs indicate that the type of treatment (MI compared with a conventional surgery) in THR has a significant effect on LOS, with MI patients having a reduced LOS after controlling for diagnosis, age, sex, obesity, comorbidities, hospital and Therefore, the results of our analysis suggest that when compared with a conventional approach to THR, an MI approach leads to a reduced LOS with no differences in total costs. On the one hand, from a hospital management perspective, considering that there is no difference in the reimbursement of MI THR and conventional THR, an MI approach in THR is attractive as a possible way of saving resources through shorter LOS. On the other hand, the MI approach is associated with higher implant costs. Incurring higher implant costs may lead to pressure to reduce costs in other cost categories to avoid the higher overall costs for MI THR compared with conventional THR. Still, with a reduced LOS and no cost differences, an MI THR approach is more attractive than a conventional approach from a hospital management perspective. Overall, the differences between the MI and the conventional approach are rather small. Thus, a clear recommendation for or against MI THR is not possible, especially as we cannot estimate the differences in medical outcome. Further studies that assess the quality of the different treatment approaches are needed.
To our knowledge, this is the first study that analyzes the effect of MI treatment for THR on hospital costs and LOS by using observational data to ensure a relatively large sample size and estimates from routine operations. If observational data are used to compare different treatment groups, however, there is a high chance for wide baseline imbalances, likely due to treatment-selection bias. To account for baseline imbalances, we implemented a propensity score matching. Because German hospital data do not make it possible to distinguish between diagnosis at admission and conditions acquired during the hospital stay, we carefully chose the diagnoses for inclusion in the propensity score model and included only those diagnoses that had very likely been recorded before the hip replacement. As a propensity score matched-pair sample does not consist of independent subjects, suitable methods for matched data have to be applied [47] . We did this by using paired t test and Wilcoxon signed-rank test for the group comparisons and GLMs with generalized estimating equations for the regression analysis [48] . The differences between the matched and the unmatched group comparisons clearly indicate how the baseline imbalances between MI and conventionally treated patients influence the results. A careful consideration of possible baseline imbalances is necessary when observational data are analyzed to assess the difference between MI and conventional THR.
Our study suffers from several limitations. Using hospital records for our analysis, the quality of the data and our results are highly determined by the coding quality of the participating hospitals. In particular, an inconsistent coding of the treatment strategy would bias the results and possibly minimize statistical differences between the two treatment groups. Because hospitals in Germany do not have a financial incentive for coding an MI technique of THR because reimbursement for MI and conventional THR does not differ, we assumed that not all hospitals in Germany code MI THR regularly and also do not code MI THR if a conventional THR had been conducted (i.e., there is no "upcoding": coding of a more expensive procedure even though the cheaper alternative is used). To ensure interpretability of our results, we included only those hospitals that affirmed a consistent coding of MI THR, resulting in a sample of only three hospitals. Hence, the sample is not representative of all hospitals in Germany, and the generalizability of our results is limited. In addition, it is not possible to make inferences about causality based on our study. Randomized controlled trials provide much stronger evidence for causality because the randomization process ensures that the groups are comparable on observed and unobserved factors. Thus, further studies, especially randomized controlled trials analyzing the economic impact of MI surgery in THR, are still needed.
Furthermore, our study suggests that future research based on observational data needs to carefully distinguish among different definitions of THR MI surgery because we find that only 3 of 23 hospitals with THR procedures consistently coded MI surgeries by using the OPS code 5-986. In fact, although 77% of the German 
Supplemental Materials
Supplemental material accompanying this article can be found in the online version as a hyperlink at http://dx.doi.org/10.1016/j.jval. 2012.06.008 or, if a hard copy of article, at www.valueinhealthjournal. com/issues (select volume, issue, and article).
Introduction
Thyroid nodules are common, affecting from 4% to 7% in the general population [1] . Fortunately, only a small proportion of these nodules (approximately 5%) are cancerous [1, 2] . Fine-needle aspiration biopsy (FNAB) is currently the standard of practice for evaluating thyroid nodules due to its low cost, low complication rate, and availability [3] . The introduction of FNAB in the early 1980s has resulted in significant economic savings and improved patient outcomes by reducing the number of diagnostic thyroid operations required and improving the detection rate of thyroid cancer [4] .
A major drawback of FNAB of thyroid nodules is the large number of indeterminate or suspicious cancer diagnoses in that often the lesions cannot definitively be classified as benign or malignant following FNAB. Clinical decision making following an indeterminate cytological result is challenging and may lead to either overtreatment or undertreatment of thyroid nodules. This diagnostic uncertainty is a consequence of not only the subjective nature of thyroid cytology but also the overlapping cytomorphologic characteristics of benign and malignant thyroid lesions. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is the result of a recent multidisciplinary effort to develop a uniform system for reporting thyroid FNAB cytological results and their clinical significance [5] . The Bethesda thyroid FNAB cytology reporting system is particularly helpful for providing a clear estimate of cancer risk and recommendations for the management of indeterminate cases (i.e., atypia of undetermined significance, follicular neoplasm, and suspicious cases). Even after following the currently recommended diagnostic algorithm, about half of the thyroid nodules operated on for an indeterminate diagnosis are eventually found to be benign [5, 6] . Therefore, the development of a new diagnostic test that can serve as an adjunct to FNAB and reduce the number of unnecessary diagnostic thyroid operations would have significant clinical and economic value.
In the current study, we aimed to 1) evaluate the overall performance of FNAB in combination with the TBSRTC (current practice) in directing thyroid nodule surgical management and 2) estimate the cost-effectiveness of using a new molecular diagnostic (DX) test as an adjunct to FNAB compared with best current practice (FNAB in combination with the TBSRTC guidelines, hereafter referred to as NoDX). We performed the analyses in scenarios for only individuals with an indeterminate FNAB cytological diagnosis, as well as for all individuals who present with thyroid nodules (i.e., including nondiagnostic, benign, and malignant cases in the target population).
Methods

Model design
We developed a patient-level discrete event simulation model by using Arena, Version 13.0 (Rockwell Software, Inc., Milwaukee, WI), to calculate the incremental cost-effectiveness of using the DX test in conjunction with FNAB relative to current practice (NoDX) in two simulated cohorts of 10,000 patients with an initial indeterminate FNAB cytological diagnosis. In a patient-level model, one hypothetical patient is created and assigned to the NoDX arm and an identical clone is created and assigned to the DX arm (see Figure 1 available in the Appendix in Supplemental Material found at http://dx.doi.org/ 10.1016/j.jval.2012.06.017). The model was run over a 10-year time horizon, and results were determined from the societal perspective. Depending on the subsequent diagnostic results in each arm, patients underwent either a total thyroidectomy or hemithyroidectomy, or alternatively were followed clinically, in accordance with the TBSRTC. In particular, we simulated the number of malignant cases across diagnostic categories, and then by comparing the final cytology and histology, each patient was classified as a true-positive, false-positive, true-negative, or false-negative cancer case. The incidence of major morbidity following surgery (i.e., permanent hypoparathyroidism and/or recurrent laryngeal nerve injury [RLNI] ) and cancer recurrence was included in the model as was cancer-related mortality.
We needed to explicitly simulate the results of sequential test outcomes for each patient to calculate the overall number of false positives and false negatives in our simulation. We also modeled the time as a continuous variable (rather than using fixed cycles). As such, we used discrete event simulation, which offers the capacity to develop continuous time, patient-level simulations with great flexibility for doing first-order and second-order sensitivity analyses [7, 8] .
Data sources and assumptions
In the simulation, following the TBSRTC classification of a nodule, there were six possible cytologic outcomes subsequent to an FNAB [5] : 1) nondiagnostic or unsatisfactory, 2) benign, 3) atypia or follicular lesion of undetermined significance, 4) follicular neoplasm, 5) suspicious for malignancy, or 6) malignant. We defined an indeterminate cytological result as an FNAB diagnosis being atypia or follicular lesion of undetermined significance, follicular neoplasm, or suspicious for malignancy. Furthermore, on the basis of review of the literature, we utilized the proportion of patients in each category, and the probabilities of malignancy for each category, to inform the progression through the model (Table 1 ) [5] . The possible pathways in the model were designed on the basis of proposed management recommendations for each cytological diagnostic category [5] .
Unlike the NoDx test arm, the diagnostic results in the DX test arm were confined to two possible diagnoses: benign or malignant. The overall prevalence of malignancy was assumed to be equal in the two arms of the model. Therefore, for a given sensi- tivity and specificity of the DX test, possible cytological and histological outcomes were simulated in the DX test arm.
Data from National Cancer Institute's Surveillance, Epidemiology, and End Results were utilized to characterize the major types of thyroid malignancy as well as the proportions of different types of cancer conditional on having a malignant nodule (Table 1) [9] . Because there are large differences in the mean age of onset for the different types of thyroid cancer (e.g., individuals diagnosed with anaplastic carcinoma are, on average, more than 20 years older than individuals diagnosed with papillary carcinoma), the expected life years lost vary widely across the different types of thyroid cancer (Table 2 ). These differences are captured in the simulation as are the differences in the mortality rates associated with different thyroid cancers [10] .
Permanent hypoparathyroidism and permanent RLNI were considered to be the two major complications of thyroid surgery. Despite being uncommon events [14] , the morbidity associated with these complications is generally chronic and thus impacts clinical outcomes and costs over a lifetime. In the model, we assumed that the failure to detect a malignancy delays necessary surgeries by 28 months on average [13, 15] and, therefore, increases the risk of cancer recurrence (relative risk ϭ 2.28) and cancer-related mortality (relative risk ϭ 2.11) [13] .
Quality of life
We included 10 health states in the model: perfect health, surgery, pre-radioactive iodine ablation, post-radioactive iodine ablation weeks 0 to 4, post-radioactive iodine ablation weeks 4 to 8, unilateral RLNI, bilateral RLNI, hypoparathyroidism, recurrence of differentiated carcinoma, and death (Table 3) . A heath state utility value (six-dimensional health state short form [derived from short form 36 health survey]) was assigned to each health state to facilitate the calculation of quality-adjusted lifeyears (QALYs) as the final model outcome [20] . For each individual in the model, QALYs were calculated by multiplying the utility values of each health state with the time spent in that health state throughout the model [16] .
Mernagh et al. [20] used health-related quality-of-life data (using short form 36 health survey questionnaire) that had been collected during an international multicenter randomized clinical trial with patients who received ablation treatment for their thyroid cancer [21] . We used the six-dimensional health state short form (derived from short form 36 health survey) utilities reported in Mernagh et al. that were derived from short form 36 health survey data in the hypothyroid arm of this clinical trial (N ϭ 30). 
Costs
The model included the cost of the DX test, total thyroidectomy, hemithyroidectomy, clinical follow-up (i.e., yearly physician visits for 5 years), radioactive iodine ablation procedure, and FNAB ( Table 3 ). The cost of the DX test was assumed to include costs of all related procedures including pathology, physician time, and specimen transport and processing. Direct costs for total thyroidectomy or hemithyroidectomy in our study were based on the results from Soria-Aledo et al. [16] . Indirect costs for total thyroidectomy or hemithyroidectomy were calculated on the basis of average lengths of hospitalizations subsequent to those surgeries and assuming an average income of $99 per day. We calculated the average annual income of men and women on the basis of US census data and assuming that 12% of the patients were men [16] . Our estimation of average income per day is also consistent with the findings from other studies including Wang et al. [17] . Both direct and indirect costs of ablation were based on estimations that have been reported in Wang et al. [17] .
Model outcomes
Simulated outcomes for each patient were recorded for the 10-year time horizon of the model (e.g., initial and final cytology, occurrence of cancer, type of cancer, hemithyroidectomy, total thyroidectomy, completion thyroidectomy, complications, and mortality). The health outcomes, in terms of QALYs and costs for each patient, were also accumulated throughout the model stages over the 10-year time horizon. In the base-case analysis, only the direct costs were included and both QALYs and costs were discounted at 3% annually. Sensitivity analyses, however, were conducted by including indirect costs, and by varying the annual discount rate from 3% to 0%. Finally, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the NoDx strategy (FNAB in combination with the TBSRTC) were also estimated and compared with the results of other studies.
We considered the societal perspective in this analysis, and the results were reported in US $, year 2011 values. All the unit costs were inflated to 2011 values in the model by using the annual changes in the consumer price index.
Univariate sensitivity analysis
In the base-case scenario, we generated 10,000 patients for each strategy, with each patient undergoing 1,000 random walks in order to minimize first-level uncertainty, resulting in 10,000,000 simulations per arm [22] . Univariate sensitivity analyses were then conducted to evaluate the effect of varying the value of model parameters over a viable range on the overall outcomes of the model. For a given level of DX test sensitivity, we reran the model by increasing the test specificity from 80% to 100% by 2.5% increments and compared the resulting incremental costs and QALYs. We repeated the same analysis by holding specificity constant and increasing sensitivity 2.5% at each step. We also explored the benefits of expanding the target population of the DX test to include all individuals who present with palpable thyroid nodules.
Probabilistic sensitivity analysis
Values of the parameters in the base-case model are point estimates drawn from various studies and are intrinsically uncertain. To capture the effect of parameter uncertainty on the outcomes, we conducted a probabilistic sensitivity analysis by assigning probability distributions to all model parameters [23] .
Results
Results of base-case analysis
In the base-case analysis, among 10,000 simulated patients with an indeterminate diagnosis in the NoDX test arm (current practice), 4,407 benign cases underwent unnecessary diagnostic surgery (false positives) while 116 cancers were not diagnosed (false negatives). In comparison, assuming a DX test sensitivity and specificity of 95%, the number of unnecessary diagnostic thyroid operations was reduced to 323 and 175 cancer cases were not diagnosed (Table 4) . Not surprisingly, the substantial reduction in the number of operations was also associated with a reduction in (Fig. 1) . Given a specificity of 95%, if the sensitivity of Dx is 87.5% or less, the incremental QALYs associated with using the DX test strategy are negative, suggesting that the DX test strategy is inferior to the NoDX test strategy in terms of clinical outcomes. As shown in Figure 1 , the incremental QALYs gained vary widely under different assumptions about the sensitivity of the DX test strategy, while changes in specificity had a smaller effect on the incremental QALYs. Inclusion of indirect costs that are generally related to productivity loss during surgical procedures and inpatient hospital stays increased the estimated savings attributable to the DX test strategy to $1251 per patient in the base-case analysis. Implementation of the DX test strategy was associated with a onetime cost per patient that is part of the overall direct cost in the DX test arm. Figure 2 shows the net monetary benefit of using different costs for the DX test strategy under the assumptions of the base-case scenario and using an arbitrary value of $50,000 per QALY gained as the threshold willingness to pay ().
When we simulated 10,000 patients with an indeterminate FNAB diagnosis in the NoDX testing strategy arm (current practice), 3,695 patients had cancer and 3,579 of those were assigned to surgery (either hemithyroidectomy or total thyroidectomy). A total of 4407 patients with benign thyroid nodules also, however, were assigned to receive a diagnostic operation. Thus, we concluded that for indeterminate cases, sensitivity, specificity, PPV, and NPV of current practice (FNAB combined with the TBSRTC) are 97%, 30%, 45%, and 94%, respectively. When we considered all thyroid nodules, the sensitivity, specificity, PPV, and NPV were 94%, 84%, 49%, and 99%, respectively.
Sensitivity analyses
The results of the univariate sensitivity analyses suggest that the cost of hemithyroidectomy, the discount rate, and the risk of permanent hypoparathyroidism have significant effects on the incremental net monetary benefit (Fig. 3) . A higher probability of malignancy among individuals with a cytological diagnosis of suspicious for malignancy, follicular neoplasm, and atypia or follicular lesion of undetermined significance was associated with a higher incremental net monetary benefit for the DX testing strategy. The results of univariate sensitivity analyses suggested that neither of these changes in the input parameters could alter the overall outcome that the DX test results in QALYs gained at lower cost over a broad range of assumptions about input parameters.
We repeated the simulation to include all individuals who present with thyroid nodules. By analyzing the results for all individuals, we evaluated the scenario where the DX test can be consistently used in conjunction with all FNABs. In addition to potentially higher sensitivity and specificity, it is expected that the new DX test requires a very small amount of cellular material relative to FNAB cytology, and therefore a significant proportion of nondiagnostic cases may be reclassified into other diagnostic categories by using the DX test. Under this scenario, sensitivity and specificity of the NoDX test strategy was estimated to be 94% and 84%, respectively. Assuming that the DX test could maintain a sensitivity and specificity of 95% in this scenario, it resulted in 0.025 QALYs gained (i.e., 25 per 1000 patients assessed) at a cost of $291 less than that in the NoDx strategy (see Table 1 The results of the probabilistic sensitivity analysis also suggest a high probability that the DX test is the dominant strategy (see Figure 2 available in the Appendix in Supplemental Material found at http://dx.doi.org/10.1016/j.jval.2012.06.017). All simulated points fall in the southeast quadrant (the DX testing strategy being more effective but less costly than the NoDx test strategy) if the cost of the Dx test was less than $500. Therefore, assuming 95% sensitivity and specificity, a DX test strategy that costs less than $500 is the dominant strategy with 100% certainty.
Discussion
The current study is the first to evaluate the incremental costeffectiveness of utilizing a molecular diagnostic testing strategy relative to the currently recommended diagnostic strategy for the diagnosis of thyroid cancer, and it is the first study to evaluate the overall performance of FNAB in combination with the TBSRTC. Given a 95% sensitivity and specificity, the utilization of the DX test strategy to improve the preoperative diagnosis of indeterminate thyroid nodules can substantially reduce the number of diagnostic operations and result in considerable QALY gains and cost savings. The potential cost savings are inversely related to the cost of the DX test strategy but remain beneficial if the cost of the Dx test is less than $1087. Provided that the sensitivities of the DX test and NoDX test strategies are comparable, the DX test strategy remains cost saving if the specificity of the Dx test is more than 80%. In contrast, a small decrement in the sensitivity of the DX test results in a larger negative effect on incremental QALYs gained, because FNAB in conjunction with the TBSRTC already provides high sensitivity at the expense of very low specificity for indeterminate cases and the negative clinical consequences of missing a malignant case are much greater than the expected consequences associated with an unnecessary diagnostic operation for a benign case. Overall, the value of the DX test strategy is largely due to Discount rate (5% to 0%) its ability to prevent unnecessary diagnostic surgical procedures following a false-positive cancer diagnosis that currently comprise approximately half of all thyroid operations [5] .
In this analysis, we compared the overall performance of the DX test strategy with that of the NoDX test strategy in terms of the number of undetected cancer cases and the number of patients with benign nodules who were assigned to undergo a thyroid operation. We defined positive cancer diagnosis as a patient who has been referred for consideration of surgery on the basis of the overall evaluation of the diagnostic strategy, as we believe that this definition is more clinically relevant. Therefore, the estimated sensitivity, specificity, PPV, and NPV reflect the overall ability of the strategy to identify cancer cases that require surgery with a high degree of accuracy. For example, the reported sensitivity for the NoDX test strategy reflects characteristics of FNAB in combination with TBSRTC rather than FNAB alone.
Previous studies have evaluated the performance of FNAB alone for the diagnosis of thyroid nodules. Gharib and Goellner [24] suggested that depending on the definition of cytological outcomes, the sensitivity of FNAB can range from 65% to 98% and the specificity can range from 72% to 100%. In a retrospective analysis of 37,895 cases reported by Ravetto et al. [25] , the sensitivity and specificity of FNAB was estimated to be 91.8% and 75.5%, respectively. In a review by Tee et al. [26] , the observed sensitivity and specificity of FNAB that has been reported also has a broad range, suggesting that the estimated characteristics of FNAB depend on the criteria and the method of measurement. Similar findings have also been reported by several other studies [6, [27] [28] [29] [30] . We believe that using different assumptions for assigning indeterminate cases into possible diagnostic outcomes has contributed to having wide variation across those studies. In contrast, we have used referral (no referral) to surgery as the criteria for defining positive (negative) diagnosis. Furthermore, in this study, we have estimated characteristics of FNAB in combination with TBSRTC rather than FNAB alone.
We have included the effect of cancer-related mortality on QALYs, but the costs that can occur in final stages of cancer (e.g., palliative care) have not been accounted for in the model. The number of individuals who develop end-stage thyroid cancer, however, was virtually identical in both arms of the model, and therefore would have limited impact on incremental costs or outcomes. The impact of surgery on QALYs was calculated only for the inpatient periods after surgery. In reality, discomfort and limitation in daily activities usually lasts for a period of time after discharge from the hospital, and therefore the impact of surgery on QALYs is likely underestimated in this model. Thus, given a higher frequency of surgeries in the NoDX test strategy, this assumption slightly favored the NoDX test strategy.
Overall, the DX test strategy appears to be the dominant diagnostic strategy, resulting in QALYs gained and reduced costs compared with current practice, if it is shown to have a high sensitivity and specificity with a reasonable cost per test. Regardless of whether the Dx test strategy is based on gene expression, protein expression, transcription analysis, immunocytochemistry, or some other type of molecular study, its ultimate benefit is primarily due to its ability to reduce the number of diagnostic operations performed for benign pathology in individuals who present with thyroid nodules by more accurately diagnosing thyroid cancer without the need for surgery. For clinical relevance and applicability, future studies evaluating molecular diagnostic tests for thyroid cancer must take economic considerations into account.
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